Onco Wiki / Biomarqueur

Expression BCL2 par IHC

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

IDBIO-BCL2-EXPRESSION-IHC
TypeBiomarqueur
Alias
Lymphome des cellules B 2BCL2BCL2 expression par immunohistochimieЕкспресія BCL2 (імуногістохімія)
Étatreviewed 2026-04-25 | pending_clinical_signoff
MaladiesDIS-AML DIS-CLL DIS-DLBCL-NOS DIS-FL DIS-MCL
SourcesSRC-NCCN-BCELL-2025

Données biomarqueurs

Type de biomarqueurprotein_expression_ihc
Mesure
MéthodeIHC sur biopsie de FFPE (anticorps anti-BCL2, 124 clones)
Unitéscategorical (positive ≥50% | negative); semi-quantitative percentage often reported
Biomarqueurs connexesBIO-BCL2-REARRANGEMENT BIO-DOUBLE-HIT

Notes

Cross-disease relevance: - **CLL/SLL**: BCL2-dependent — venetoclax (BCL-2 inhibitor) is highly active. Universal CLL marker; drives VenO 1L choice for high-risk. - **MCL**: cyclin-D1+ MCL is also BCL2+; predicts venetoclax-rituximab sensitivity in r/r — emerging 2L+ pathway. - **FL**: defining via t(14;18) IGH/BCL2 (~85%) — over-expression blocks apoptosis. Tazemetostat (EZH2 inhibitor) emerging in EZH2-mut r/r FL. - **DLBCL**: double-expressor (BCL2+ ≥50% IHC + MYC+ ≥40% IHC at protein level, distinct from FISH double-hit) is adverse but does NOT change 1L regimen per current evidence. - **HGBL-DH**: BCL2 rearrangement is part of double-hit definition (with MYC + optionally BCL6). - **MM**: t(11;14) MM subset highly venetoclax-sensitive; emerging therapy. Direct algorithm-driving currently: indirectly via BIO-DOUBLE-HIT in HGBL-DH + via venetoclax-eligible flag in CLL high-risk. Future: drive r/r 2L+ venetoclax pathway across all BCL2-dependent diseases.

Utilisé par

Pertinence thérapeutique

Biomarqueur

Chapitres du manuel

Indication

Questionnaires